The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer

2017 ◽  
Vol 81 (1) ◽  
pp. 131-139 ◽  
Author(s):  
Takeshi Masuda ◽  
Chihiro Hirano ◽  
Yasushi Horimasu ◽  
Taku Nakashima ◽  
Shintarou Miyamoto ◽  
...  
2016 ◽  
Vol 103 (1) ◽  
pp. 60-65 ◽  
Author(s):  
Nobuhiro Asai ◽  
Eisuke Katsuda ◽  
Rie Hamanaka ◽  
Kenshi Kosaka ◽  
Ayako Matsubara ◽  
...  

Introduction Patients with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are at high risk of acute exacerbation of ILD (AE-ILD) when treated with systemic chemotherapy. Standard treatment for NSCLC complicated by ILD has not been established. Purpose and methods To examine whether the type of ILD categorized by the official ATS/ERS/JRS/ALAT statement as “idiopathic pulmonary fibrosis (IPF) by high-resolution computed tomography (HRCT)” could predict chemotherapy-induced AE-ILD in NSCLC patients with ILD, we retrospectively reviewed all patients with NSCLC complicated by ILD who had received chemotherapy at our institute from January 2007 until December 2013. Patients’ characteristics, pathology and clinical staging of lung cancer, chemotherapy, type of ILD and AE-ILD during chemotherapy were evaluated. ILD was classified according to the statement as follows: usual interstitial pneumonia (UIP), possible UIP, and inconsistent with a UIP pattern. Results A total of 46 patients had pre-existing ILD and received chemotherapy. The mean age was 73 years (range 46-83 years). Fifteen (32.6%) of 46 patients with ILD developed chemotherapy-induced AE-ILD, which was seen more frequently in patients with ILD with a UIP pattern or possible UIP pattern than in patients with a pattern inconsistent with UIP (80% versus 9.7%, p<0.001). Multivariate analyses including age, sex, performance status and radiographic patterns of ILD showed that the presence of a UIP or possible UIP pattern was an independent risk factor for chemotherapy-induced AE-ILD. Conclusions ILD with a UIP pattern or possible UIP pattern by the classification could be a risk factor for AE-ILD in NSCLC patients with ILD.


2017 ◽  
Vol 7 (4) ◽  
pp. 604-608 ◽  
Author(s):  
Hideyuki Niwa ◽  
Yoshiro Nakahara ◽  
Masanori Yokoba ◽  
Hisashi Mitsufuji ◽  
Jiichiro Sasaki ◽  
...  

2020 ◽  
Vol 59 (16) ◽  
pp. 1939-1945 ◽  
Author(s):  
Tetsuo Fujita ◽  
Tsuguko Kuroki ◽  
Nami Hayama ◽  
Yuka Shiraishi ◽  
Hiroyuki Amano ◽  
...  

2019 ◽  
Vol 32 (3) ◽  
pp. 236 ◽  
Author(s):  
Andreia Tereso ◽  
Luís Carreto ◽  
Manuela Baptista ◽  
Maria Amélia Almeida

The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors. One example of tyrosine kinase inhibitors is crizotinib, an anaplastic lymphoma tyrosine kinase inhibitor, which targets an echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase gene fusion. This mutation is found in only 2% to 7% of non-small-cell lung cancer cases. Although these new therapies have shown promising results, the occurrence of interstitial lung disease as a side effect could be problematic. As the diagnosis of drug-related-interstitial lung disease is difficult to make, computed tomography is an important diagnostic tool. The recognition of computed tomography manifestations of tyrosine kinase inhibitors -induced interstitial lung disease is the key for an early recognition and management of this pulmonary toxicity. We aim to raise awareness of tyrosine kinase inhibitors-induced interstitial lung disease, by reporting the first case of a Portuguese patient treated with crizotinib for non-small-cell lung cancer who developed drug-induced interstitial lung disease.


Sign in / Sign up

Export Citation Format

Share Document